Eledon Pharmaceuticals, Inc.

NASDAQ:ELDN

2.81 (USD) • At close October 17, 2024
Bedrijfsnaam Eledon Pharmaceuticals, Inc.
Symbool ELDN
Munteenheid USD
Prijs 2.81
Beurswaarde 111,432,517
Dividendpercentage 0%
52-weken bereik 1.07 - 3.349
Industrie Biotechnology
Sector Healthcare
CEO Dr. David-Alexandre C. Gros M.D., Ph.D.
Website https://eledon.com

An error occurred while fetching data.

Over Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on

Vergelijkbare Aandelen

Eargo, Inc. logo

Eargo, Inc.

EAR

2.57 USD

Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc.

AQST

4.92 USD

NexImmune, Inc. logo

NexImmune, Inc.

NEXI

0.32 USD

STRATA Skin Sciences, Inc. logo

STRATA Skin Sciences, Inc.

SSKN

2.96 USD

Alimera Sciences, Inc. logo

Alimera Sciences, Inc.

ALIM

5.54 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)